These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 33774117)

  • 1. Oral lipid nanomedicines: Current status and future perspectives in cancer treatment.
    El Moukhtari SH; Rodríguez-Nogales C; Blanco-Prieto MJ
    Adv Drug Deliv Rev; 2021 Jun; 173():238-251. PubMed ID: 33774117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lipid nanomedicines for anticancer drug therapy.
    Estella-Hermoso de Mendoza A; Campanero MA; Mollinedo F; Blanco-Prieto MJ
    J Biomed Nanotechnol; 2009 Aug; 5(4):323-43. PubMed ID: 20055079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced oral absorption and anticancer efficacy of cabazitaxel by overcoming intestinal mucus and epithelium barriers using surface polyethylene oxide (PEO) decorated positively charged polymer-lipid hybrid nanoparticles.
    Ren T; Wang Q; Xu Y; Cong L; Gou J; Tao X; Zhang Y; He H; Yin T; Zhang H; Zhang Y; Tang X
    J Control Release; 2018 Jan; 269():423-438. PubMed ID: 29133120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid-based drug delivery systems for cancer treatment.
    Arias JL; Clares B; Morales ME; Gallardo V; Ruiz MA
    Curr Drug Targets; 2011 Jul; 12(8):1151-65. PubMed ID: 21443475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A critical review of lipid-based nanoparticles for taxane delivery.
    Feng L; Mumper RJ
    Cancer Lett; 2013 Jul; 334(2):157-75. PubMed ID: 22796606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanomedicines for cancer therapy: current status, challenges and future prospects.
    Bor G; Mat Azmi ID; Yaghmur A
    Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives.
    Edis Z; Wang J; Waqas MK; Ijaz M; Ijaz M
    Int J Nanomedicine; 2021; 16():1313-1330. PubMed ID: 33628022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
    Chen Z; Zheng Y; Shi Y; Cui Z
    Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smart Drug-Delivery Systems for Cancer Nanotherapy.
    Sanchez-Moreno P; Ortega-Vinuesa JL; Peula-Garcia JM; Marchal JA; Boulaiz H
    Curr Drug Targets; 2018 Feb; 19(4):339-359. PubMed ID: 27231107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solid Matrix Based Lipidic Nanoparticles in Oral Cancer Chemotherapy: Applications and Pharmacokinetics.
    Ahmad J; Amin S; Rahman M; Rub RA; Singhal M; Ahmad MZ; Rahman Z; Addo RT; Ahmad FJ; Mushtaq G; Kamal MA; Akhter S
    Curr Drug Metab; 2015; 16(8):633-44. PubMed ID: 26264206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanotechnological carriers for cancer chemotherapy: the state of the art.
    Estanqueiro M; Amaral MH; Conceição J; Sousa Lobo JM
    Colloids Surf B Biointerfaces; 2015 Feb; 126():631-48. PubMed ID: 25591851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted multifunctional lipid-based nanocarriers for image-guided drug delivery.
    Koning GA; Krijger GC
    Anticancer Agents Med Chem; 2007 Jul; 7(4):425-40. PubMed ID: 17630918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-based nanocarriers as an alternative for oral delivery of poorly water- soluble drugs: peroral and mucosal routes.
    Silva AC; Santos D; Ferreira D; Lopes CM
    Curr Med Chem; 2012; 19(26):4495-510. PubMed ID: 22834821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydrophobic ion pairing as a strategy to improve drug encapsulation into lipid nanocarriers for the cancer treatment.
    Oliveira MS; Goulart GCA; Ferreira LAM; Carneiro G
    Expert Opin Drug Deliv; 2017 Aug; 14(8):983-995. PubMed ID: 27892713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DePEGylation strategies to increase cancer nanomedicine efficacy.
    Kong L; Campbell F; Kros A
    Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining Nanomedicine and Immunotherapy.
    Shi Y; Lammers T
    Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancement in design of nanostructured lipid carriers for cancer targeting and theranostic application.
    Rizwanullah M; Ahmad MZ; Garg A; Ahmad J
    Biochim Biophys Acta Gen Subj; 2021 Sep; 1865(9):129936. PubMed ID: 34058266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
    Tracey SR; Smyth P; Barelle CJ; Scott CJ
    Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomedicine to target multidrug resistant tumors.
    Lepeltier E; Rijo P; Rizzolio F; Popovtzer R; Petrikaite V; Assaraf YG; Passirani C
    Drug Resist Updat; 2020 Sep; 52():100704. PubMed ID: 32512316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.